CoChat

Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force

Harris, Russell, Donahue, Katrina, Rathore, Saif S., Frame, Paul, Woolf, Steven H., Lohr, Kathleen N. · 2003 · Annals of Internal Medicine
Cited by 113

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Type 2 diabetes mellitus is associated with a heavy burden of suffering. Screening for diabetes is controversial. PURPOSE: To examine the evidence that screening and earlier treatment are effective in reducing morbidity and mortality associated with diabetes. DATA SOURCES: MEDLINE, the Cochrane Library, reviews, and experts, all of which addressed key questions about screening. STUDY SELECTION: Studies that provided information about the existence and length of an asymptomatic phase of diabetes; studies that addressed the accuracy and reliability of screening tests; and randomized, controlled trials with health outcomes for various treatment strategies were selected. DATA EXTRACTION: Two reviewers abstracted relevant information using standardized abstraction forms and graded articles according to U.S. Preventive Services Task Force criteria. DATA SYNTHESIS: No randomized, controlled trial of screening for diabetes has been performed. Type 2 diabetes mellitus includes an asymptomatic preclinical phase; the length of this phase is unknown. Screening tests can detect diabetes in its preclinical phase. Over the 10 to 15 years after clinical diagnosis, tight glycemic control probably reduces the risk for blindness and end-stage renal disease, and aggressive control of hypertension, lipid therapy, and aspirin use reduce cardiovascular events. The magnitude of the benefit is larger for cardiovascular risk reduction than for tight glycemic control. The additional benefit of starting these treatments in the preclinical phase, after detection by screening, is uncertain but is probably also greater for cardiovascular risk reduction. CONCLUSIONS: The interventions that are most clearly beneficial during the preclinical phase are those that affect the risk for cardiovascular disease. The magnitude of additional benefit of initiating tight glycemic control during the preclinical phase is uncertain but probably small.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-138-3-200302040-00015

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 113

Metadata

Authors
Harris, R., Donahue, K., Rathore, S. S., Frame, P., Woolf, S. H., & Lohr, K. N.
Venue
Annals of Internal Medicine
Published
2003-02-04
Volume
138
Issue
3
Pages
215-229
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2130749027
Cited by
113
References
40
FWCI
11.87
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force. https://app.cochat.ai/papers/10.7326/0003-4819-138-3-200302040-00015
The paper
Harris, R., Donahue, K., Rathore, S. S., Frame, P., Woolf, S. H., & Lohr, K. N. (2003). Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-138-3-200302040-00015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.